title: Regenerative therapy of infrabony defects with or without systemic doxycycline. A randomized placebo-controlled trial.
abstract: OBJECTIVE
  Comparison of regenerative therapy of infrabony defects with and without administration of postsurgical systemic doxycycline (DOXY).
  
  
  METHODS
  In each of 61 patients one infrabony defect was treated with enamel matrix derivative (EMD), EMD plus filler or membrane at two centres. By random assignment patients received either 200 mg DOXY per day or placebo (PLAC) for 7 days after surgery. Prior to and 6 months after surgery probing pocket depths (PPD) and vertical attachment level (PAL-V) were obtained.
  
  
  RESULTS
  Fifty-four patients (DOXY: 27; PLAC: 27) were re-examined after 6 months and had been treated exclusively with EMD. Seven to 8 days after surgery 81% of defects in both groups showed complete flap closure. In both groups significant (p < 0.001) PPD reduction (DOXY: 3.87 ± 1.44 mm; PLAC: 3.67 ± 1.30 mm) and PAL-V gain (DOXY: 3.11 ± 1.50 mm; PLAC: 3.32 ± 1.83 mm) were observed. However, the differences failed to be statistically significant (PPD: 0.20; p = 0.588; PAL-V: 0.21; p = 0.657).
  
  
  CONCLUSIONS
  Two hundred milligram systemic DOXY administered for 7 days after therapy of infrabony defects with EMD failed to result in better PPD reduction and PAL-V gain compared with PLAC which may be due to low power (50%) and, thus, random chance.
authors.affiliation: Department of Periodontology, Center for Dental, Oral, and Maxillofacial Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main, Frankfurt/Main, Germany.
authors.forename: Lasse
authors.initials: L
authors.lastname: Röllke
authors.forename: Beate
authors.initials: B
authors.lastname: Schacher
authors.forename: Martin
authors.initials: M
authors.lastname: Wohlfeil
authors.forename: Ti-Sun
authors.initials: TS
authors.lastname: Kim
authors.forename: Jens
authors.initials: J
authors.lastname: Kaltschmitt
authors.forename: Jörg
authors.initials: J
authors.lastname: Krieger
authors.forename: Diana M
authors.initials: DM
authors.lastname: Krigar
authors.forename: Peter
authors.initials: P
authors.lastname: Reitmeir
authors.forename: Peter
authors.initials: P
authors.lastname: Eickholz
mesh_terms: D016976:Aggregatibacter actinomycetemcomitans / Q000187:drug effects; D016301:Alveolar Bone Loss / Q000188:drug therapy / Q000601:surgery*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D058491:Bacterial Load / Q000187:drug effects; D001439:Bacteroides / Q000187:drug effects; D001861:Bone Regeneration / Q000502:physiology*; D003746:Dental Enamel Proteins / Q000627:therapeutic use; D003774:Dental Plaque Index; D004311:Double-Blind Method; D004318:Doxycycline / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D016967:Fusobacterium nucleatum / Q000187:drug effects; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods*; D006801:Humans; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000601:surgery; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000601:surgery; D010919:Placebos; D016966:Porphyromonas gingivalis / Q000187:drug effects; D018713:Prevotella intermedia / Q000187:drug effects; D016300:Radiography, Bitewing / Q000379:methods; D016896:Treatment Outcome; D048373:Treponema denticola / Q000187:drug effects; D014945:Wound Healing / Q000502:physiology
chemical_list: D000900:Anti-Bacterial Agents; D003746:Dental Enamel Proteins; D008567:Membranes, Artificial; D010919:Placebos; C109069:enamel matrix proteins; D004318:Doxycycline